Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience.
Kiyoka SawadaKentaro NakayamaKohei NakamuraYuki YoshimuraSultana RaziaMasako IshikawaHitomi YamashitaTomoka IshibashiSeiya SatoSatoru KyoPublished in: Healthcare (Basel, Switzerland) (2021)
Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examine the efficacy and clinical feasibility of genotype-matched therapy. Target sequencing was performed in 20 cases of gynecological cancers (cervical cancer, 6; endometrial cancer, 6; and ovarian cancer, 6). Both actionable and druggable genes were identified in 95% (19/20) of the cases. Among them, seven patients (35%) received genotype-matched therapy, which was effective in three patients. Of the three patients, one patient with a PTEN mutation received everolimus, another patient with a TSC2 mutation received everolimus and letrozole, and the patient with a BRIP1 mutation received olaparib. Subsequently, disease control in these three patients lasted for more than half a year. However, all patients relapsed between 9 and 13 months after the initiation of genotype-matched therapy. In this study, the response rate of genotype-matched therapy was 43% (3/7), which may have contributed to improved prognoses. Therefore, genotype-matched therapies may help patients with refractory gynecological cancers achieve better outcomes.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- poor prognosis
- chronic kidney disease
- prognostic factors
- stem cells
- peritoneal dialysis
- type diabetes
- squamous cell carcinoma
- young adults
- radiation therapy
- metabolic syndrome
- diffuse large b cell lymphoma
- copy number
- long non coding rna
- signaling pathway
- dna methylation
- cell therapy
- combination therapy
- polycystic ovary syndrome
- early breast cancer